Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study

Jennifer Soung; Yong Cui; Robert Bissonnette; Mark G. Lebwohl; Álvaro González-Cantero; Andreas Pinter; Phoebe Rich; Vimal H. Prajapati; Megan Miller-Kassamali; Joseph Cafone; Jingzhi Jiang; Shu Li; Ya Wen Yang; Andrew E. Pink

doi:10.1016/j.jaad.2026.05.048

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study

Jennifer Soung
, Yong Cui
, Robert Bissonnette
, Mark G. Lebwohl
, Álvaro González-Cantero
, Andreas Pinter
, Phoebe Rich
, Vimal H. Prajapati
, Megan Miller-Kassamali
, Joseph Cafone
, Jingzhi Jiang
, Shu Li
, Ya Wen Yang
, Andrew E. Pink

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Journal	Journal of the American Academy of Dermatology
DOIs	https://doi.org/10.1016/j.jaad.2026.05.048
State	Accepted/In press - 2026

Keywords

adults
ICONIC-LEAD
icotrokinra
oral peptide
psoriasis
responder
retreatment
withdrawal

Access to Document

10.1016/j.jaad.2026.05.048

Cite this

Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., González-Cantero, Á., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. (Accepted/In press). Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.05.048

@article{d2be9d8251be40f19d661d4f482f145a,

title = "Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study",

keywords = "adults, ICONIC-LEAD, icotrokinra, oral peptide, psoriasis, responder, retreatment, withdrawal",

author = "Jennifer Soung and Yong Cui and Robert Bissonnette and Lebwohl, \{Mark G.\} and {\'A}lvaro Gonz{\'a}lez-Cantero and Andreas Pinter and Phoebe Rich and Prajapati, \{Vimal H.\} and Megan Miller-Kassamali and Joseph Cafone and Jingzhi Jiang and Shu Li and Yang, \{Ya Wen\} and Pink, \{Andrew E.\}",

year = "2026",

doi = "10.1016/j.jaad.2026.05.048",

language = "English",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

}

Soung, J, Cui, Y, Bissonnette, R, Lebwohl, MG, González-Cantero, Á, Pinter, A, Rich, P, Prajapati, VH, Miller-Kassamali, M, Cafone, J, Jiang, J, Li, S, Yang, YW & Pink, AE 2026, 'Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study', Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.05.048

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study. / Soung, Jennifer; Cui, Yong; Bissonnette, Robert et al.
In: Journal of the American Academy of Dermatology, 2026.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis

T2 - Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study

AU - Soung, Jennifer

AU - Cui, Yong

AU - Bissonnette, Robert

AU - Lebwohl, Mark G.

AU - González-Cantero, Álvaro

AU - Pinter, Andreas

AU - Rich, Phoebe

AU - Prajapati, Vimal H.

AU - Miller-Kassamali, Megan

AU - Cafone, Joseph

AU - Jiang, Jingzhi

AU - Li, Shu

AU - Yang, Ya Wen

AU - Pink, Andrew E.

PY - 2026

Y1 - 2026

KW - adults

KW - ICONIC-LEAD

KW - icotrokinra

KW - oral peptide

KW - psoriasis

KW - responder

KW - retreatment

KW - withdrawal

UR - https://www.scopus.com/pages/publications/105042612666

U2 - 10.1016/j.jaad.2026.05.048

DO - 10.1016/j.jaad.2026.05.048

M3 - Article

C2 - 42176706

AN - SCOPUS:105042612666

SN - 0190-9622

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

ER -

Soung J, Cui Y, Bissonnette R, Lebwohl MG, González-Cantero Á, Pinter A et al. Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study. Journal of the American Academy of Dermatology. 2026. doi: 10.1016/j.jaad.2026.05.048